公开(公告)号：US20240033331A1

公开(公告)日：2024-02-01

申请号：US18376677

申请日：2023-10-04

申请人： Horizon Therapeutics USA, Inc.

发明人： Jeffrey D. KENT ,  Brian LAMOREAUX

IPC分类号： A61K38/44 ,  A61K31/5377 ,  A61P19/06 ,  A61K47/60 ,  A61K9/00 ,  A61K31/365

CPC分类号： A61K38/44 ,  A61K31/5377 ,  A61P19/06 ,  A61K47/60 ,  A61K9/0053 ,  A61K31/365 ,  A61K31/165

摘要： The disclosure provides methods of treating gout in patients comprising administering a PEGylated uricase. Also provided are methods of treating gout in patients comprising co-administering a PEGylated uricase and MMF. Also provided are methods of reducing intolerance to a PEGylated uricase and prolonging the urate lowering effect comprising co-administration of the PEGylated uricase and MMF.

公开(公告)号：US20230085022A1

公开(公告)日：2023-03-16

申请号：US16347900

申请日：2017-11-10

申请人： Horizon Therapeutics USA, Inc.

发明人： Jeffrey D. KENT ,  Brian LAMOREAUX

IPC分类号： A61K38/44 ,  A61K9/00 ,  A61K31/573 ,  A61K31/519 ,  A61K31/381 ,  A61P37/00

摘要： Described herein are methods for reducing an antibody response to uricase therapy, improving the treatment of gout, reducing uric acid levels, and preventing and/or delaying infusion reactions. The methods may include administration of a uricase and a steroid as described herein.

公开(公告)号：US20230173035A1

公开(公告)日：2023-06-08

申请号：US17955437

申请日：2022-09-28

申请人： Horizon Therapeutics USA, Inc.

发明人： Jeffrey D. KENT ,  Brian LAMOREAUX ,  John BOTSON ,  Jeff PETERSON

IPC分类号： A61K38/44 ,  A61K47/34 ,  A61P19/06 ,  A61K31/519

CPC分类号： A61K38/44 ,  A61K47/34 ,  A61P19/06 ,  A61K31/519

摘要： The disclosure provides methods of treating gout in patients comprising administering a PEGylated uricase. Also provided are methods of treating gout in patients comprising co-administering a PEGylated uricase and methotrexate (MTX). Also provided are methods of reducing immunogenicity of a PEGylated uricase and prolonging the urate lowering effect comprising co-administration of the PEGylated uricase and MTX.